Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'

Executive Summary

GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 shows the UK group remains a serious contender in the innovative cancer space, its oncology R&D head tells Scrip.

You may also be interested in...



Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.

Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.

Adaptimmune Hits High With TCR Platform Success With GSK Licensed Product

The T-cell therapy company has been tipped as a potential leader in a potentially disruptive field as new data support wide application in cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel